Latest News for BIAF
bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technology reports continued acceleration in commercial sales for its CyPath® Lung diagnostic with more than 200% growth year-over-year.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports on preclinical findings that demonstrate siRNA therapy kills skin cancer cells while sparing healthy cells.
JERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, closed its previously announced public offering…
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of $3.2 million offering.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BIAF.
U.S. House Trading
No House trades found for BIAF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.